Published in Chem Biol on January 01, 2005
Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36
Iterative in situ click chemistry creates antibody-like protein-capture agents. Angew Chem Int Ed Engl (2009) 1.64
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A (2005) 1.48
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol (2008) 1.42
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev (2010) 1.14
Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. Mol Ther Nucleic Acids (2014) 1.09
Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano (2012) 1.06
Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv (2010) 1.05
Cell-specific aptamers as emerging therapeutics. J Nucleic Acids (2011) 1.04
Binding of a structured D-RNA molecule by an L-RNA aptamer. J Am Chem Soc (2013) 0.97
Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics. Angew Chem Int Ed Engl (2010) 0.95
Nearest neighbor parameters for Watson-Crick complementary heteroduplexes formed between 2'-O-methyl RNA and RNA oligonucleotides. Nucleic Acids Res (2006) 0.94
Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. Biologics (2007) 0.92
Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells. J Biomed Biotechnol (2010) 0.92
Single-step nanoplasmonic VEGF165 aptasensor for early cancer diagnosis. ACS Nano (2012) 0.90
Towards XNA nanotechnology: new materials from synthetic genetic polymers. Trends Biotechnol (2014) 0.89
Aptamer-Drug Conjugates. Bioconjug Chem (2015) 0.89
Aptamers and their applications in nanomedicine. Small (2015) 0.88
RAPID-SELEX for RNA aptamers. PLoS One (2013) 0.88
Directed polymerase evolution. FEBS Lett (2013) 0.86
Highly stable aptamers selected from a 2'-fully modified fGmH RNA library for targeting biomaterials. Biomaterials (2015) 0.84
Strategies for the discovery of therapeutic aptamers. Expert Opin Drug Discov (2011) 0.84
Structural basis for specific inhibition of Autotaxin by a DNA aptamer. Nat Struct Mol Biol (2016) 0.83
Nucleic acids in human glioma treatment: innovative approaches and recent results. J Signal Transduct (2012) 0.83
Transcription yield of fully 2'-modified RNA can be increased by the addition of thermostabilizing mutations to T7 RNA polymerase mutants. Nucleic Acids Res (2015) 0.82
Tracking the emergence of high affinity aptamers for rhVEGF165 during capillary electrophoresis-systematic evolution of ligands by exponential enrichment using high throughput sequencing. Anal Chem (2013) 0.81
In vitro selection using modified or unnatural nucleotides. Curr Protoc Nucleic Acid Chem (2002) 0.81
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems. Int J Mol Sci (2015) 0.81
Artificial specific binders directly recovered from chemically modified nucleic acid libraries. J Nucleic Acids (2012) 0.81
In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies. RNA Biol (2016) 0.81
Recent developments in protein and cell-targeted aptamer selection and applications. Curr Med Chem (2011) 0.81
Modified Nucleoside Triphosphates for In-vitro Selection Techniques. Front Chem (2016) 0.81
A survey of advancements in nucleic acid-based logic gates and computing for applications in biotechnology and biomedicine. Chem Commun (Camb) (2015) 0.80
Aptamers as a novel tool for diagnostics and therapy. Invest New Drugs (2015) 0.80
Aptamers in diagnostics and treatment of viral infections. Viruses (2015) 0.80
Aptamers as both drugs and drug-carriers. Biomed Res Int (2014) 0.79
Therapeutic aptamers: developmental potential as anticancer drugs. BMB Rep (2015) 0.79
Highly parallel translation of DNA sequences into small molecules. PLoS One (2012) 0.79
Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice. Toxicol Appl Pharmacol (2015) 0.79
Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells. PLoS One (2013) 0.78
Escort aptamers: new tools for the targeted delivery of therapeutics into cells. Acta Naturae (2011) 0.78
Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy. RNA Biol (2015) 0.77
From selection hits to clinical leads: progress in aptamer discovery. Mol Ther Methods Clin Dev (2016) 0.77
Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics. Indian J Pharm Sci (2010) 0.76
Evoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Res (2016) 0.76
Aptamer technology for tracking cells' status & function. Mol Cell Ther (2014) 0.76
In vitro selection using modified or unnatural nucleotides. Curr Protoc Nucleic Acid Chem (2014) 0.76
The expanding world of DNA and RNA. Curr Opin Chem Biol (2016) 0.75
The synthesis of 2'-methylseleno adenosine and guanosine 5'-triphosphates. Bioorg Med Chem (2012) 0.75
A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers. Nucleic Acid Ther (2016) 0.75
Suppression of FOXM1 Transcriptional Activities via a Single-Stranded DNA Aptamer Generated by SELEX. Sci Rep (2017) 0.75
Synthetic biology approaches to biological containment: pre-emptively tackling potential risks. Essays Biochem (2016) 0.75
Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction? Pharmaceuticals (Basel) (2012) 0.75
Coupling Aptamers to Short Interfering RNAs as Therapeutics. Pharmaceuticals (Basel) (2011) 0.75
Sequential injection analysis for optimization of molecular biology reactions. Anal Chem (2011) 0.75
Post-ExSELEX stabilization of an unnatural-base DNA aptamer targeting VEGF165 toward pharmaceutical applications. Nucleic Acids Res (2016) 0.75
Development of an aptamer-based affinity purification method for vascular endothelial growth factor. Biotechnol Rep (Amst) (2015) 0.75
Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth. Theranostics (2017) 0.75
Aptamer Cell-Based Selection: Overview and Advances. Biomedicines (2017) 0.75
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer. Int J Mol Sci (2017) 0.75
Origins of the enhanced affinity of RNA-protein interactions triggered by RNA phosphorodithioate backbone modification. Chem Commun (Camb) (2017) 0.75
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol (2013) 3.56
Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol (2013) 2.41
A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis (2010) 1.95
Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res (2007) 1.83
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood (2011) 1.72
Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood (2010) 1.66
Ready for genomic medicine? Perspectives of health care decision makers. Arch Intern Med (2005) 1.60
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res (2011) 1.51
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther (2011) 1.45
Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication. Proc Natl Acad Sci U S A (2004) 1.37
Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res (2004) 1.36
Cross-calibration and minimum precision standards for dual-energy X-ray absorptiometry: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.30
Radiofrequency identification technology can standardize and document blood collections and transfusions. Transfusion (2007) 1.28
Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol (2006) 1.23
Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist (2003) 1.21
AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res (2010) 1.17
Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis (2011) 1.14
Rescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: use of a pp38 mutant to validate the technology for the study of gene function. Proc Natl Acad Sci U S A (2002) 1.13
Recognition of planar and nonplanar ligands in the malachite green-RNA aptamer complex. Chembiochem (2004) 1.11
Identification of a novel noncatalytic bicarbonate binding site in eubacterial beta-carbonic anhydrase. Biochemistry (2006) 1.09
Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. Am J Pathol (2011) 1.08
Advances in understanding the process of epileptogenesis based on patient material: what can the patient tell us? Epilepsia (2003) 1.08
Analysis of initial slow waves (ISWs) at the seizure onset in patients with drug resistant temporal lobe epilepsy. Epilepsia (2007) 1.04
ADP-specific sensors enable universal assay of protein kinase activity. Chem Biol (2004) 1.04
Specific phosphorothioate substitutions probe the active site of Bacillus subtilis ribonuclease P. RNA (2002) 1.03
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther (2011) 0.99
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst (2004) 0.99
Protein-precursor tRNA contact leads to sequence-specific recognition of 5' leaders by bacterial ribonuclease P. J Mol Biol (2009) 0.99
Epileptogenesis after self-sustaining status epilepticus. Epilepsia (2002) 0.97
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res (2012) 0.97
Irreducible anterior and posterior dislocation of the shoulder due to incarceration of the biceps tendon. Int J Shoulder Surg (2010) 0.97
Transitions between irregular and rhythmic firing patterns in excitatory-inhibitory neuronal networks. J Comput Neurosci (2007) 0.96
Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides (2005) 0.96
Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J Cell Physiol (2006) 0.96
Randomized trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: cost-effectiveness analysis. Int J Technol Assess Health Care (2006) 0.95
Co-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells. Nucleic Acids Res (2006) 0.95
Iterative evaluation in a mobile counseling and testing program to reach people of color at risk for HIV--new strategies improve program acceptability, effectiveness, and evaluation capabilities. AIDS Educ Prev (2011) 0.95
Kinetic characterization of wild-type and proton transfer-impaired variants of beta-carbonic anhydrase from Arabidopsis thaliana. Arch Biochem Biophys (2002) 0.91
2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. Oligonucleotides (2006) 0.89
Alveolar adenoma. Ann Thorac Surg (2004) 0.89
The mechanism of ubihydroquinone oxidation at the Qo-site of the cytochrome bc1 complex. Biochim Biophys Acta (2013) 0.89
A novel strategy for selection of allosteric ribozymes yields RiboReporter sensors for caffeine and aspartame. Nucleic Acids Res (2004) 0.87
Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV. Vaccine (2008) 0.86
Creation of diversity in the animal virus world by inter-species and intra-species recombinations: lessons learned from poultry viruses. Virus Genes (2007) 0.86
Polymorphisms in the repeat long regions of oncogenic and attenuated pathotypes of Marek's disease virus 1. Virus Genes (2006) 0.85
Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-β enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs (2010) 0.85
ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol (2012) 0.84
Transcriptional profiling of Marek's disease virus genes during cytolytic and latent infection. Virus Genes (2008) 0.83
Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor. Pharm Res (2006) 0.82
Endovascular treatment for dural arteriovenous fistulae of the superior petrosal sinus. Neurosurgery (2003) 0.80
The effect of the time interval between exposures on the susceptibility of chickens to superinfection with Marek's disease virus. Avian Dis (2010) 0.79
Audit of local recurrence following breast conservation surgery with 5-mm target margin and hypofractionated 40-Gray breast radiotherapy for invasive breast cancer. Ann R Coll Surg Engl (2010) 0.79
Virulent Marek's disease virus generated from infectious bacterial artificial chromosome clones with complete DNA sequence and the implication of viral genetic homogeneity in pathogenesis. J Gen Virol (2010) 0.79
Characterization of reticuloendotheliosis virus isolates obtained from broiler breeders, turkeys, and prairie chickens located in various geographical regions in the United States. Avian Pathol (2010) 0.79
Insertion of reticuloendotheliosis virus long terminal repeat into a bacterial artificial chromosome clone of a very virulent Marek's disease virus alters its pathogenicity. Avian Pathol (2012) 0.79
Competition between two virulent Marek's disease virus strains in vivo. Avian Pathol (2012) 0.78
Special delivery: microRNA-200-containing extracellular vesicles provide metastatic message to distal tumor cells. J Clin Invest (2014) 0.78
Optimization and comparison of balloon-based partial breast brachytherapy using a single source, a standard plan line source, and both forward and inverse planned multilumen techniques. Brachytherapy (2012) 0.78
Paramedics as decision makers on the activation of the catheterization laboratory in the presence of acute ST-elevation myocardial infarction. J Electrocardiol (2010) 0.78
Laparoscopic salpingo-oophorectomy for ovarian ablation in women with hormone-sensitive breast cancer. Int J Gynaecol Obstet (2011) 0.77
Characterization of LORF11, a unique gene common to the three Marek's disease virus serotypes. Avian Dis (2007) 0.77
Detection and differentiation of CVI988 (Rispens vaccine) from other serotype 1 Marek's disease viruses. Avian Dis (2014) 0.77
Universal strategies for the DNA-encoding of libraries of small molecules using the chemical ligation of oligonucleotide tags. Artif DNA PNA XNA (2014) 0.77
Detection and localization of avian alphaherpesviruses in embryonic tissues following in ovo exposure. Virus Res (2004) 0.76
Multiple vibration intensities and frequencies for bone mineral density improvement. Conf Proc IEEE Eng Med Biol Soc (2008) 0.76
Pathogenicity of two recombinant avian leukosis viruses. Avian Dis (2003) 0.76
Old dog, new tricks: extracellular domain arginine methylation regulates EGFR function. J Clin Invest (2015) 0.75
Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist's decision. Oncology (2013) 0.75
Artificially inserting a reticuloendotheliosis virus long terminal repeat into a bacterial artificial chromosome clone of Marek's disease virus (MDV) alters expression of nearby MDV genes. Virus Genes (2011) 0.75
Isoform-selective ATAD2 chemical probe with novel chemical structure and unusual mode of action. ACS Chem Biol (2017) 0.75
Gene expression profiling in rMd5- and rMd5deltameq-infected chickens. Avian Dis (2011) 0.75
Ability of MEQ-deleted MDV vaccine candidates to adversely affect lymphoid organs and chicken weight gain. Avian Dis (2012) 0.75
Radiologic case study. Reflex sympathetic dystrophy syndrome. Orthopedics (2004) 0.75
Creating more trauma-informed services for children using assessment-focused tools. Child Welfare (2008) 0.75
Radiologic case study. Pipkin type II fracture of the right femoral head. Orthopedics (2004) 0.75
Creating trauma-informed child welfare systems using a community assessment process. Child Welfare (2011) 0.75
Deletion of the Marek's disease virus UL41 gene (vhs) has no measurable effect on latency or pathogenesis. Virus Genes (2008) 0.75
(90)Y radioembolization: embolization of the gastroduodenal artery is not always appropriate. Cardiovasc Intervent Radiol (2010) 0.75
Radiologic case study. Complete radiocarpal dislocation with an associated radial styloid fracture. Orthopedics (2004) 0.75
Promising practices and strategies for using trauma-informed child welfare practice to improve foster care placement stability: a breakthrough series collaborative. Child Welfare (2011) 0.75
Outcomes of anterior cruciate ligament reconstruction in patients older than 50 years of age. Bull Hosp Jt Dis (2013) (2014) 0.75
Managing traumatized children: a trauma systems perspective. Curr Opin Pediatr (2010) 0.75
Quantitative evaluation of viral fitness due to a single nucleotide polymorphism in the Marek's disease virus UL41 gene via an in vitro competition assay. J Virol Methods (2007) 0.75